Docetaxel (Taxotere)
Also known as N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol, NSC 628503 or RP 56976.
Contents |
General information
Class/mechanism: Taxane; disrupts normal microtubular function. Binds to free tubulin, promotes their assembly into stable microtubules, and inhibits their disassembly, which inhibits mitosis.[1][2]
Route: IV
Extravasation: irritant, rare vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bone cancer
- Breast cancer
- Cancer of unknown primary
- Cervical cancer
- Esophageal cancer
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
Patient drug information
- Docetaxel (Taxotere) patient drug information (Chemocare)[3]
- Docetaxel (Taxotere) package insert pages 16-17[1]
- Docetaxel (Taxotere) patient drug information (UpToDate)[4]
References
- Drug index
- Chemotherapy
- Irritant chemotherapy
- Vesicant chemotherapy
- Taxanes
- Bone cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Esophageal cancer medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Prostate cancer medications
